Global Oncology Drugs Market Overview
Oncology Drugs Market size is projected to reach USD XX Million by 2028 from an estimated USD XX Million in 2021, growing at a CAGR of xx% globally.Cancer is defined as the abnormal growth of body cells. Normal cells have a well-defined, regulated pattern of growth. When cancer starts, a collection of cells begins to expand randomly and uncontrollably, forming lumps or tumors. A malignant tumor grows indefinitely and can spread to other parts of the body. Oncology medications are therapeutics used to treat cancer. Oncology drugs are a diverse group of treatments that include chemotherapeutic agents, targeted therapies, immunotherapies, and hormone therapies. Although oncology is typically observed as a single therapy area, it encompasses more than 20 different indications. According to McKinsey, breast cancer, multiple myeloma, non-small cell lung cancer (NSCLC), prostate cancer, and non-lymphoma Hodgkin's (NHL) accounted for the majority of oncology drug sales in 2019, totaling $90 billion (68 percent of the market). This is predicted to expand to $141 billion in sales by 2024 (64 percent of the market), owing primarily to the increase in PD-(L)1 sales for NSCLC. The rising number of cancer patients is likely to drive the growth of the oncology drugs market over the forecasted period.
Covid-19 Impact On Oncology Drugs Market
The novel coronavirus SARS-COV-2 caused an outbreak of the COVID-19 disease, which the World Health Organization declared a pandemic on March 22, 2020. The rapid spread of this virus has had a severe influence on all sectors of health care around the world, including cancer care. To begin with, cancer patients are a vulnerable population when it comes to contracting the virus. A big Chinese study found that the infection rate in cancer patients doubled when compared to the general population. Cancer treatments have been reduced in several nations, with screening programs halted, surgical delays, and chemotherapy treatment interruptions. As a result, there will be more late diagnoses, with patients presenting with severe disease and fewer treatment options. Furthermore, it hampered clinical trials and drug supply to patients. According to a Cancer Research Institute and IQVIA survey published in Nature Reviews Drug Discovery, patient enrolment in oncology clinical trials in the United States and Europe was severely hampered during the early phases of the pandemic, where 60% and 86% of institutions, respectively, were enrolling new patients at a lower rate, hampered the R&D programs of several key players. To summarize, the growing vaccination rate coupled with an increase in investments is expected to boost the development of the oncology drugs market throughout the forecast period.
Market Segmentation
Players Covered in Oncology Drugs market are :
- Genentech
- Inc. (US)
- Eli Lilly and Company (United States)
- Pfizer Inc. (US)
- Bristol-Myers Squibb Company (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- AstraZeneca (UK)
- GlaxoSmithKline plc. (UK)
- Sanofi (France)
- Bayer AG (Germany)
Key Industry Developments of Oncology Drugs Market
In March 2022, Novartis announced today that PluvictoTM has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic).
In October 2021, Genentech, a member of the Roche Group, announced that the FDA has approved Tecentriq® (atezolizumab) as adjuvant treatment after surgery as well as platinum-based treatment for persons with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L11 %, according to an FDA-approved test.
| Oncology Drugs Market - Global Size & Upcoming Industry Trends | |||
|---|---|---|---|
| Segmentations | by Type |
| |
| by Therapy |
| ||
| by Cancer Type |
| ||
| by Dosage Form |
| ||
| by Region |
| ||
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Drug Class
3.2 By Therapy
3.3 By Cancer Type
3.4 By Dosage Form
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
3.5.1 Drivers
3.5.2 Restraints
3.5.3 Opportunities
3.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 4: Oncology Drugs Market by Drug Class
4.1 Oncology Drugs Market Overview Snapshot and Growth Engine
4.2 Oncology Drugs Market Overview
4.3 Targeted Drugs
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size (2016-2028F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Targeted Drugs: Grographic Segmentation
4.4 Hormonal Drugs
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size (2016-2028F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Hormonal Drugs: Grographic Segmentation
4.5 Cytotoxic Drugs
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size (2016-2028F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Cytotoxic Drugs: Grographic Segmentation
4.6 Others
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size (2016-2028F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Others: Grographic Segmentation
Chapter 5: Oncology Drugs Market by Therapy
5.1 Oncology Drugs Market Overview Snapshot and Growth Engine
5.2 Oncology Drugs Market Overview
5.3 Targeted Therapy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Targeted Therapy: Grographic Segmentation
5.4 Chemotherapy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Chemotherapy: Grographic Segmentation
5.5 Immunotherapy
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Immunotherapy: Grographic Segmentation
Chapter 6: Oncology Drugs Market by Cancer Type
6.1 Oncology Drugs Market Overview Snapshot and Growth Engine
6.2 Oncology Drugs Market Overview
6.3 Colorectal Cancer
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Colorectal Cancer: Grographic Segmentation
6.4 Lung Cancer
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Lung Cancer: Grographic Segmentation
6.5 Stomach Cancer
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Stomach Cancer: Grographic Segmentation
6.6 Prostate Cancer
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2028F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Prostate Cancer: Grographic Segmentation
6.7 Breast Cancer
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2016-2028F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Breast Cancer: Grographic Segmentation
Chapter 7: Oncology Drugs Market by Dosage Form
7.1 Oncology Drugs Market Overview Snapshot and Growth Engine
7.2 Oncology Drugs Market Overview
7.3 Solid
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size (2016-2028F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Solid: Grographic Segmentation
7.4 Liquid
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size (2016-2028F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Liquid: Grographic Segmentation
Chapter 8: Company Profiles and Competitive Analysis
8.1 Competitive Landscape
8.1.1 Competitive Positioning
8.1.2 Oncology Drugs Sales and Market Share By Players
8.1.3 Industry BCG Matrix
8.1.4 Ansoff Matrix
8.1.5 Oncology Drugs Industry Concentration Ratio (CR5 and HHI)
8.1.6 Top 5 Oncology Drugs Players Market Share
8.1.7 Mergers and Acquisitions
8.1.8 Business Strategies By Top Players
8.2 GENENTECH
8.2.1 Company Overview
8.2.2 Key Executives
8.2.3 Company Snapshot
8.2.4 Operating Business Segments
8.2.5 Product Portfolio
8.2.6 Business Performance
8.2.7 Key Strategic Moves and Recent Developments
8.2.8 SWOT Analysis
8.3 INC. (US)
8.4 ELI LILLY AND COMPANY (UNITED STATES)
8.5 PFIZER INC. (US)
8.6 BRISTOL-MYERS SQUIBB COMPANY (US)
8.7 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
8.8 NOVARTIS AG (SWITZERLAND)
8.9 ASTRAZENECA (UK)
8.10 GLAXOSMITHKLINE PLC. (UK)
8.11 SANOFI (FRANCE)
8.12 BAYER AG (GERMANY)
Chapter 9: Global Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
9.1 Market Overview
9.2 Historic and Forecasted Market Size By Drug Class
9.2.1 Targeted Drugs
9.2.2 Hormonal Drugs
9.2.3 Cytotoxic Drugs
9.2.4 Others
9.3 Historic and Forecasted Market Size By Therapy
9.3.1 Targeted Therapy
9.3.2 Chemotherapy
9.3.3 Immunotherapy
9.4 Historic and Forecasted Market Size By Cancer Type
9.4.1 Colorectal Cancer
9.4.2 Lung Cancer
9.4.3 Stomach Cancer
9.4.4 Prostate Cancer
9.4.5 Breast Cancer
9.5 Historic and Forecasted Market Size By Dosage Form
9.5.1 Solid
9.5.2 Liquid
Chapter 10: North America Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Drug Class
10.4.1 Targeted Drugs
10.4.2 Hormonal Drugs
10.4.3 Cytotoxic Drugs
10.4.4 Others
10.5 Historic and Forecasted Market Size By Therapy
10.5.1 Targeted Therapy
10.5.2 Chemotherapy
10.5.3 Immunotherapy
10.6 Historic and Forecasted Market Size By Cancer Type
10.6.1 Colorectal Cancer
10.6.2 Lung Cancer
10.6.3 Stomach Cancer
10.6.4 Prostate Cancer
10.6.5 Breast Cancer
10.7 Historic and Forecasted Market Size By Dosage Form
10.7.1 Solid
10.7.2 Liquid
10.8 Historic and Forecast Market Size by Country
10.8.1 U.S.
10.8.2 Canada
10.8.3 Mexico
Chapter 11: Europe Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Drug Class
11.4.1 Targeted Drugs
11.4.2 Hormonal Drugs
11.4.3 Cytotoxic Drugs
11.4.4 Others
11.5 Historic and Forecasted Market Size By Therapy
11.5.1 Targeted Therapy
11.5.2 Chemotherapy
11.5.3 Immunotherapy
11.6 Historic and Forecasted Market Size By Cancer Type
11.6.1 Colorectal Cancer
11.6.2 Lung Cancer
11.6.3 Stomach Cancer
11.6.4 Prostate Cancer
11.6.5 Breast Cancer
11.7 Historic and Forecasted Market Size By Dosage Form
11.7.1 Solid
11.7.2 Liquid
11.8 Historic and Forecast Market Size by Country
11.8.1 Germany
11.8.2 U.K.
11.8.3 France
11.8.4 Italy
11.8.5 Russia
11.8.6 Spain
Chapter 12: Asia-Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Drug Class
12.4.1 Targeted Drugs
12.4.2 Hormonal Drugs
12.4.3 Cytotoxic Drugs
12.4.4 Others
12.5 Historic and Forecasted Market Size By Therapy
12.5.1 Targeted Therapy
12.5.2 Chemotherapy
12.5.3 Immunotherapy
12.6 Historic and Forecasted Market Size By Cancer Type
12.6.1 Colorectal Cancer
12.6.2 Lung Cancer
12.6.3 Stomach Cancer
12.6.4 Prostate Cancer
12.6.5 Breast Cancer
12.7 Historic and Forecasted Market Size By Dosage Form
12.7.1 Solid
12.7.2 Liquid
12.8 Historic and Forecast Market Size by Country
12.8.1 China
12.8.2 India
12.8.3 Japan
12.8.4 Southeast Asia
Chapter 13: South America Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Drug Class
13.4.1 Targeted Drugs
13.4.2 Hormonal Drugs
13.4.3 Cytotoxic Drugs
13.4.4 Others
13.5 Historic and Forecasted Market Size By Therapy
13.5.1 Targeted Therapy
13.5.2 Chemotherapy
13.5.3 Immunotherapy
13.6 Historic and Forecasted Market Size By Cancer Type
13.6.1 Colorectal Cancer
13.6.2 Lung Cancer
13.6.3 Stomach Cancer
13.6.4 Prostate Cancer
13.6.5 Breast Cancer
13.7 Historic and Forecasted Market Size By Dosage Form
13.7.1 Solid
13.7.2 Liquid
13.8 Historic and Forecast Market Size by Country
13.8.1 Brazil
13.8.2 Argentina
Chapter 14: Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Drug Class
14.4.1 Targeted Drugs
14.4.2 Hormonal Drugs
14.4.3 Cytotoxic Drugs
14.4.4 Others
14.5 Historic and Forecasted Market Size By Therapy
14.5.1 Targeted Therapy
14.5.2 Chemotherapy
14.5.3 Immunotherapy
14.6 Historic and Forecasted Market Size By Cancer Type
14.6.1 Colorectal Cancer
14.6.2 Lung Cancer
14.6.3 Stomach Cancer
14.6.4 Prostate Cancer
14.6.5 Breast Cancer
14.7 Historic and Forecasted Market Size By Dosage Form
14.7.1 Solid
14.7.2 Liquid
14.8 Historic and Forecast Market Size by Country
14.8.1 Saudi Arabia
14.8.2 South Africa
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Drug Class
3.2 By Therapy
3.3 By Cancer Type
3.4 By Dosage Form
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
3.5.1 Drivers
3.5.2 Restraints
3.5.3 Opportunities
3.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 4: Oncology Drugs Market by Drug Class
4.1 Oncology Drugs Market Overview Snapshot and Growth Engine
4.2 Oncology Drugs Market Overview
4.3 Targeted Drugs
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size (2016-2028F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Targeted Drugs: Grographic Segmentation
4.4 Hormonal Drugs
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size (2016-2028F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Hormonal Drugs: Grographic Segmentation
4.5 Cytotoxic Drugs
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size (2016-2028F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Cytotoxic Drugs: Grographic Segmentation
4.6 Others
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size (2016-2028F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Others: Grographic Segmentation
Chapter 5: Oncology Drugs Market by Therapy
5.1 Oncology Drugs Market Overview Snapshot and Growth Engine
5.2 Oncology Drugs Market Overview
5.3 Targeted Therapy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Targeted Therapy: Grographic Segmentation
5.4 Chemotherapy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Chemotherapy: Grographic Segmentation
5.5 Immunotherapy
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Immunotherapy: Grographic Segmentation
Chapter 6: Oncology Drugs Market by Cancer Type
6.1 Oncology Drugs Market Overview Snapshot and Growth Engine
6.2 Oncology Drugs Market Overview
6.3 Colorectal Cancer
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Colorectal Cancer: Grographic Segmentation
6.4 Lung Cancer
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Lung Cancer: Grographic Segmentation
6.5 Stomach Cancer
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Stomach Cancer: Grographic Segmentation
6.6 Prostate Cancer
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2028F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Prostate Cancer: Grographic Segmentation
6.7 Breast Cancer
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2016-2028F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Breast Cancer: Grographic Segmentation
Chapter 7: Oncology Drugs Market by Dosage Form
7.1 Oncology Drugs Market Overview Snapshot and Growth Engine
7.2 Oncology Drugs Market Overview
7.3 Solid
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size (2016-2028F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Solid: Grographic Segmentation
7.4 Liquid
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size (2016-2028F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Liquid: Grographic Segmentation
Chapter 8: Company Profiles and Competitive Analysis
8.1 Competitive Landscape
8.1.1 Competitive Positioning
8.1.2 Oncology Drugs Sales and Market Share By Players
8.1.3 Industry BCG Matrix
8.1.4 Ansoff Matrix
8.1.5 Oncology Drugs Industry Concentration Ratio (CR5 and HHI)
8.1.6 Top 5 Oncology Drugs Players Market Share
8.1.7 Mergers and Acquisitions
8.1.8 Business Strategies By Top Players
8.2 GENENTECH
8.2.1 Company Overview
8.2.2 Key Executives
8.2.3 Company Snapshot
8.2.4 Operating Business Segments
8.2.5 Product Portfolio
8.2.6 Business Performance
8.2.7 Key Strategic Moves and Recent Developments
8.2.8 SWOT Analysis
8.3 INC. (US)
8.4 ELI LILLY AND COMPANY (UNITED STATES)
8.5 PFIZER INC. (US)
8.6 BRISTOL-MYERS SQUIBB COMPANY (US)
8.7 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
8.8 NOVARTIS AG (SWITZERLAND)
8.9 ASTRAZENECA (UK)
8.10 GLAXOSMITHKLINE PLC. (UK)
8.11 SANOFI (FRANCE)
8.12 BAYER AG (GERMANY)
Chapter 9: Global Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
9.1 Market Overview
9.2 Historic and Forecasted Market Size By Drug Class
9.2.1 Targeted Drugs
9.2.2 Hormonal Drugs
9.2.3 Cytotoxic Drugs
9.2.4 Others
9.3 Historic and Forecasted Market Size By Therapy
9.3.1 Targeted Therapy
9.3.2 Chemotherapy
9.3.3 Immunotherapy
9.4 Historic and Forecasted Market Size By Cancer Type
9.4.1 Colorectal Cancer
9.4.2 Lung Cancer
9.4.3 Stomach Cancer
9.4.4 Prostate Cancer
9.4.5 Breast Cancer
9.5 Historic and Forecasted Market Size By Dosage Form
9.5.1 Solid
9.5.2 Liquid
Chapter 10: North America Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Drug Class
10.4.1 Targeted Drugs
10.4.2 Hormonal Drugs
10.4.3 Cytotoxic Drugs
10.4.4 Others
10.5 Historic and Forecasted Market Size By Therapy
10.5.1 Targeted Therapy
10.5.2 Chemotherapy
10.5.3 Immunotherapy
10.6 Historic and Forecasted Market Size By Cancer Type
10.6.1 Colorectal Cancer
10.6.2 Lung Cancer
10.6.3 Stomach Cancer
10.6.4 Prostate Cancer
10.6.5 Breast Cancer
10.7 Historic and Forecasted Market Size By Dosage Form
10.7.1 Solid
10.7.2 Liquid
10.8 Historic and Forecast Market Size by Country
10.8.1 U.S.
10.8.2 Canada
10.8.3 Mexico
Chapter 11: Europe Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Drug Class
11.4.1 Targeted Drugs
11.4.2 Hormonal Drugs
11.4.3 Cytotoxic Drugs
11.4.4 Others
11.5 Historic and Forecasted Market Size By Therapy
11.5.1 Targeted Therapy
11.5.2 Chemotherapy
11.5.3 Immunotherapy
11.6 Historic and Forecasted Market Size By Cancer Type
11.6.1 Colorectal Cancer
11.6.2 Lung Cancer
11.6.3 Stomach Cancer
11.6.4 Prostate Cancer
11.6.5 Breast Cancer
11.7 Historic and Forecasted Market Size By Dosage Form
11.7.1 Solid
11.7.2 Liquid
11.8 Historic and Forecast Market Size by Country
11.8.1 Germany
11.8.2 U.K.
11.8.3 France
11.8.4 Italy
11.8.5 Russia
11.8.6 Spain
Chapter 12: Asia-Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Drug Class
12.4.1 Targeted Drugs
12.4.2 Hormonal Drugs
12.4.3 Cytotoxic Drugs
12.4.4 Others
12.5 Historic and Forecasted Market Size By Therapy
12.5.1 Targeted Therapy
12.5.2 Chemotherapy
12.5.3 Immunotherapy
12.6 Historic and Forecasted Market Size By Cancer Type
12.6.1 Colorectal Cancer
12.6.2 Lung Cancer
12.6.3 Stomach Cancer
12.6.4 Prostate Cancer
12.6.5 Breast Cancer
12.7 Historic and Forecasted Market Size By Dosage Form
12.7.1 Solid
12.7.2 Liquid
12.8 Historic and Forecast Market Size by Country
12.8.1 China
12.8.2 India
12.8.3 Japan
12.8.4 Southeast Asia
Chapter 13: South America Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Drug Class
13.4.1 Targeted Drugs
13.4.2 Hormonal Drugs
13.4.3 Cytotoxic Drugs
13.4.4 Others
13.5 Historic and Forecasted Market Size By Therapy
13.5.1 Targeted Therapy
13.5.2 Chemotherapy
13.5.3 Immunotherapy
13.6 Historic and Forecasted Market Size By Cancer Type
13.6.1 Colorectal Cancer
13.6.2 Lung Cancer
13.6.3 Stomach Cancer
13.6.4 Prostate Cancer
13.6.5 Breast Cancer
13.7 Historic and Forecasted Market Size By Dosage Form
13.7.1 Solid
13.7.2 Liquid
13.8 Historic and Forecast Market Size by Country
13.8.1 Brazil
13.8.2 Argentina
Chapter 14: Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Drug Class
14.4.1 Targeted Drugs
14.4.2 Hormonal Drugs
14.4.3 Cytotoxic Drugs
14.4.4 Others
14.5 Historic and Forecasted Market Size By Therapy
14.5.1 Targeted Therapy
14.5.2 Chemotherapy
14.5.3 Immunotherapy
14.6 Historic and Forecasted Market Size By Cancer Type
14.6.1 Colorectal Cancer
14.6.2 Lung Cancer
14.6.3 Stomach Cancer
14.6.4 Prostate Cancer
14.6.5 Breast Cancer
14.7 Historic and Forecasted Market Size By Dosage Form
14.7.1 Solid
14.7.2 Liquid
14.8 Historic and Forecast Market Size by Country
14.8.1 Saudi Arabia
14.8.2 South Africa
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
| Oncology Drugs Market - Global Size & Upcoming Industry Trends | |||
|---|---|---|---|
| Segmentations | by Type |
| |
| by Therapy |
| ||
| by Cancer Type |
| ||
| by Dosage Form |
| ||
| by Region |
| ||
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ONCOLOGY DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ONCOLOGY DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ONCOLOGY DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. ONCOLOGY DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. ONCOLOGY DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. ONCOLOGY DRUGS MARKET BY DRUG CLASS
TABLE 008. TARGETED DRUGS MARKET OVERVIEW (2016-2028)
TABLE 009. HORMONAL DRUGS MARKET OVERVIEW (2016-2028)
TABLE 010. CYTOTOXIC DRUGS MARKET OVERVIEW (2016-2028)
TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 012. ONCOLOGY DRUGS MARKET BY THERAPY
TABLE 013. TARGETED THERAPY MARKET OVERVIEW (2016-2028)
TABLE 014. CHEMOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 015. IMMUNOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 016. ONCOLOGY DRUGS MARKET BY CANCER TYPE
TABLE 017. COLORECTAL CANCER MARKET OVERVIEW (2016-2028)
TABLE 018. LUNG CANCER MARKET OVERVIEW (2016-2028)
TABLE 019. STOMACH CANCER MARKET OVERVIEW (2016-2028)
TABLE 020. PROSTATE CANCER MARKET OVERVIEW (2016-2028)
TABLE 021. BREAST CANCER MARKET OVERVIEW (2016-2028)
TABLE 022. ONCOLOGY DRUGS MARKET BY DOSAGE FORM
TABLE 023. SOLID MARKET OVERVIEW (2016-2028)
TABLE 024. LIQUID MARKET OVERVIEW (2016-2028)
TABLE 025. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 026. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 027. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 028. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 029. N ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 030. EUROPE ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 031. EUROPE ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 032. EUROPE ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 033. EUROPE ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 034. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 035. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 036. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 037. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 038. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 039. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 044. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 045. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 046. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 047. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 048. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 049. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 050. GENENTECH: SNAPSHOT
TABLE 051. GENENTECH: BUSINESS PERFORMANCE
TABLE 052. GENENTECH: PRODUCT PORTFOLIO
TABLE 053. GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. INC. (US): SNAPSHOT
TABLE 054. INC. (US): BUSINESS PERFORMANCE
TABLE 055. INC. (US): PRODUCT PORTFOLIO
TABLE 056. INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY AND COMPANY (UNITED STATES): SNAPSHOT
TABLE 057. ELI LILLY AND COMPANY (UNITED STATES): BUSINESS PERFORMANCE
TABLE 058. ELI LILLY AND COMPANY (UNITED STATES): PRODUCT PORTFOLIO
TABLE 059. ELI LILLY AND COMPANY (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. PFIZER INC. (US): SNAPSHOT
TABLE 060. PFIZER INC. (US): BUSINESS PERFORMANCE
TABLE 061. PFIZER INC. (US): PRODUCT PORTFOLIO
TABLE 062. PFIZER INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. BRISTOL-MYERS SQUIBB COMPANY (US): SNAPSHOT
TABLE 063. BRISTOL-MYERS SQUIBB COMPANY (US): BUSINESS PERFORMANCE
TABLE 064. BRISTOL-MYERS SQUIBB COMPANY (US): PRODUCT PORTFOLIO
TABLE 065. BRISTOL-MYERS SQUIBB COMPANY (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): SNAPSHOT
TABLE 066. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 067. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 068. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. NOVARTIS AG (SWITZERLAND): SNAPSHOT
TABLE 069. NOVARTIS AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 070. NOVARTIS AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 071. NOVARTIS AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. ASTRAZENECA (UK): SNAPSHOT
TABLE 072. ASTRAZENECA (UK): BUSINESS PERFORMANCE
TABLE 073. ASTRAZENECA (UK): PRODUCT PORTFOLIO
TABLE 074. ASTRAZENECA (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. GLAXOSMITHKLINE PLC. (UK): SNAPSHOT
TABLE 075. GLAXOSMITHKLINE PLC. (UK): BUSINESS PERFORMANCE
TABLE 076. GLAXOSMITHKLINE PLC. (UK): PRODUCT PORTFOLIO
TABLE 077. GLAXOSMITHKLINE PLC. (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. SANOFI (FRANCE): SNAPSHOT
TABLE 078. SANOFI (FRANCE): BUSINESS PERFORMANCE
TABLE 079. SANOFI (FRANCE): PRODUCT PORTFOLIO
TABLE 080. SANOFI (FRANCE): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. BAYER AG (GERMANY): SNAPSHOT
TABLE 081. BAYER AG (GERMANY): BUSINESS PERFORMANCE
TABLE 082. BAYER AG (GERMANY): PRODUCT PORTFOLIO
TABLE 083. BAYER AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ONCOLOGY DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ONCOLOGY DRUGS MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. TARGETED DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 013. HORMONAL DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 014. CYTOTOXIC DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 016. ONCOLOGY DRUGS MARKET OVERVIEW BY THERAPY
FIGURE 017. TARGETED THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 018. CHEMOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 019. IMMUNOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 020. ONCOLOGY DRUGS MARKET OVERVIEW BY CANCER TYPE
FIGURE 021. COLORECTAL CANCER MARKET OVERVIEW (2016-2028)
FIGURE 022. LUNG CANCER MARKET OVERVIEW (2016-2028)
FIGURE 023. STOMACH CANCER MARKET OVERVIEW (2016-2028)
FIGURE 024. PROSTATE CANCER MARKET OVERVIEW (2016-2028)
FIGURE 025. BREAST CANCER MARKET OVERVIEW (2016-2028)
FIGURE 026. ONCOLOGY DRUGS MARKET OVERVIEW BY DOSAGE FORM
FIGURE 027. SOLID MARKET OVERVIEW (2016-2028)
FIGURE 028. LIQUID MARKET OVERVIEW (2016-2028)
FIGURE 029. NORTH AMERICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. EUROPE ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. ASIA PACIFIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. SOUTH AMERICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ONCOLOGY DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ONCOLOGY DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ONCOLOGY DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. ONCOLOGY DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. ONCOLOGY DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. ONCOLOGY DRUGS MARKET BY DRUG CLASS
TABLE 008. TARGETED DRUGS MARKET OVERVIEW (2016-2028)
TABLE 009. HORMONAL DRUGS MARKET OVERVIEW (2016-2028)
TABLE 010. CYTOTOXIC DRUGS MARKET OVERVIEW (2016-2028)
TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 012. ONCOLOGY DRUGS MARKET BY THERAPY
TABLE 013. TARGETED THERAPY MARKET OVERVIEW (2016-2028)
TABLE 014. CHEMOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 015. IMMUNOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 016. ONCOLOGY DRUGS MARKET BY CANCER TYPE
TABLE 017. COLORECTAL CANCER MARKET OVERVIEW (2016-2028)
TABLE 018. LUNG CANCER MARKET OVERVIEW (2016-2028)
TABLE 019. STOMACH CANCER MARKET OVERVIEW (2016-2028)
TABLE 020. PROSTATE CANCER MARKET OVERVIEW (2016-2028)
TABLE 021. BREAST CANCER MARKET OVERVIEW (2016-2028)
TABLE 022. ONCOLOGY DRUGS MARKET BY DOSAGE FORM
TABLE 023. SOLID MARKET OVERVIEW (2016-2028)
TABLE 024. LIQUID MARKET OVERVIEW (2016-2028)
TABLE 025. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 026. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 027. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 028. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 029. N ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 030. EUROPE ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 031. EUROPE ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 032. EUROPE ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 033. EUROPE ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 034. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 035. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 036. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 037. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 038. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 039. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 044. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 045. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 046. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 047. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 048. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 049. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 050. GENENTECH: SNAPSHOT
TABLE 051. GENENTECH: BUSINESS PERFORMANCE
TABLE 052. GENENTECH: PRODUCT PORTFOLIO
TABLE 053. GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. INC. (US): SNAPSHOT
TABLE 054. INC. (US): BUSINESS PERFORMANCE
TABLE 055. INC. (US): PRODUCT PORTFOLIO
TABLE 056. INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY AND COMPANY (UNITED STATES): SNAPSHOT
TABLE 057. ELI LILLY AND COMPANY (UNITED STATES): BUSINESS PERFORMANCE
TABLE 058. ELI LILLY AND COMPANY (UNITED STATES): PRODUCT PORTFOLIO
TABLE 059. ELI LILLY AND COMPANY (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. PFIZER INC. (US): SNAPSHOT
TABLE 060. PFIZER INC. (US): BUSINESS PERFORMANCE
TABLE 061. PFIZER INC. (US): PRODUCT PORTFOLIO
TABLE 062. PFIZER INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. BRISTOL-MYERS SQUIBB COMPANY (US): SNAPSHOT
TABLE 063. BRISTOL-MYERS SQUIBB COMPANY (US): BUSINESS PERFORMANCE
TABLE 064. BRISTOL-MYERS SQUIBB COMPANY (US): PRODUCT PORTFOLIO
TABLE 065. BRISTOL-MYERS SQUIBB COMPANY (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): SNAPSHOT
TABLE 066. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 067. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 068. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. NOVARTIS AG (SWITZERLAND): SNAPSHOT
TABLE 069. NOVARTIS AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 070. NOVARTIS AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 071. NOVARTIS AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. ASTRAZENECA (UK): SNAPSHOT
TABLE 072. ASTRAZENECA (UK): BUSINESS PERFORMANCE
TABLE 073. ASTRAZENECA (UK): PRODUCT PORTFOLIO
TABLE 074. ASTRAZENECA (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. GLAXOSMITHKLINE PLC. (UK): SNAPSHOT
TABLE 075. GLAXOSMITHKLINE PLC. (UK): BUSINESS PERFORMANCE
TABLE 076. GLAXOSMITHKLINE PLC. (UK): PRODUCT PORTFOLIO
TABLE 077. GLAXOSMITHKLINE PLC. (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. SANOFI (FRANCE): SNAPSHOT
TABLE 078. SANOFI (FRANCE): BUSINESS PERFORMANCE
TABLE 079. SANOFI (FRANCE): PRODUCT PORTFOLIO
TABLE 080. SANOFI (FRANCE): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. BAYER AG (GERMANY): SNAPSHOT
TABLE 081. BAYER AG (GERMANY): BUSINESS PERFORMANCE
TABLE 082. BAYER AG (GERMANY): PRODUCT PORTFOLIO
TABLE 083. BAYER AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ONCOLOGY DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ONCOLOGY DRUGS MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. TARGETED DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 013. HORMONAL DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 014. CYTOTOXIC DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 016. ONCOLOGY DRUGS MARKET OVERVIEW BY THERAPY
FIGURE 017. TARGETED THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 018. CHEMOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 019. IMMUNOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 020. ONCOLOGY DRUGS MARKET OVERVIEW BY CANCER TYPE
FIGURE 021. COLORECTAL CANCER MARKET OVERVIEW (2016-2028)
FIGURE 022. LUNG CANCER MARKET OVERVIEW (2016-2028)
FIGURE 023. STOMACH CANCER MARKET OVERVIEW (2016-2028)
FIGURE 024. PROSTATE CANCER MARKET OVERVIEW (2016-2028)
FIGURE 025. BREAST CANCER MARKET OVERVIEW (2016-2028)
FIGURE 026. ONCOLOGY DRUGS MARKET OVERVIEW BY DOSAGE FORM
FIGURE 027. SOLID MARKET OVERVIEW (2016-2028)
FIGURE 028. LIQUID MARKET OVERVIEW (2016-2028)
FIGURE 029. NORTH AMERICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. EUROPE ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. ASIA PACIFIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. SOUTH AMERICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
Frequently Asked Questions :
What would be forecast period in the market research report?
The forecast period in the market research report is 2022-2028.
Who are the key players in Oncology Drugs market?
The key players mentioned are Genentech, Inc. (US), Eli Lilly and Company (United States), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), GlaxoSmithKline plc. (UK), Sanofi (France), Bayer AG (Germany).
What are the segments of Oncology Drugs market?
The Oncology Drugs market is segmented into Drug Class, Therapy, Cancer Type, Dosage Form and region. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain; Rest of Europe), Asia-Pacific (China; India; Japan; Southeast Asia; Rest of APAC), Middle East & Africa (GCC Countries; South Africa; Rest of MEA), South America (Brazil; Argentina; Rest of South America).
What is the Oncology Drugs market?
Oncology Drugs Market size is projected to reach xxxx units by 2028 from an estimated xxxx unit in 2021, growing at a CAGR of xx% globally.
How big is the Oncology Drugs market?
The global Oncology Drugs market size was estimated at USD XX billion in 2021 and is expected to reach USD XX billion in 2028.
